Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-genes produced anti-tumour effects

British Journal of Cancer

Volumn 105, Issue 9, 2011, Pages 1302-1312

  Li, Q ^a,b   Kawamura, K ^a   Okamoto, S ^b   Fujie, H ^c   Numasaki, M ^c   Namba, M ^d   Nagata, M ^a   Shimada, H ^e   Kobayashi, H ^b   Tagawa, M ^a,b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c JOSAI UNIVERSITY   (Japan)

^d Niimi University   (Japan)

^e TOHO UNIVERSITY   (Japan)

Author keywords

adenovirus; apoptosis; gene therapy; IFN l; oesophageal carcinoma

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CD31 ANTIGEN; CD69 ANTIGEN; CYTOCHROME C; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CARCINOGENICITY; CARCINOMA CELL; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 80055019697     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.379     Document Type: Article

References (28)

1. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J (2005) IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289: G960-G968 (Pubitemid 41532589)
2. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8: 237-249 (Pubitemid 36749609)
3. Clohessy JG, Zhuang J, de Boer J, Gil-Gómez G, Brady HJ (2006) Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 281: 5750-5759 (Pubitemid 43847674)
4. Compton T (1993) An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection. J Virol 67: 3644-3648 (Pubitemid 23143748)
5. Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26: S112-S121
6. Fritz V, Jorgensen C (2008) Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther 3: 32-42 (Pubitemid 352024865)
7. Fushimi K, Iijima M, Gao C, Kondo T, Tsuji T, Hashimoto T, Mihara K, Namba M (1997) Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and X-rays. Int J Cancer 70: 135-140 (Pubitemid 27059717)
8. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, Houkin K, Matsunaga T, Niitsu Y (2005) Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 96: 149-156 (Pubitemid 40575915)
9. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP (2003) IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77 (Pubitemid 36109115)
10. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV (2006) Characterization of the mouse IFN-l ligand-receptor system: IFN-ls exhibit antitumor activity against B16 melanoma. Cancer Res 66: 4468-4477
11. Li M, Liu X, Zhou Y, Su SB (2009) Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86: 23-32
12. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M (2010) Interferon-l induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46: 180-190
13. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV (2008) Regulation of apoptosis by type III interferons. Cell Prolif 241: 960-979
14. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM (2006) Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898 (Pubitemid 44958521)
15. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M (2005) Biological activity of interleukins-28 and-29: comparison with type I interferons. Cytokine 31: 109-118 (Pubitemid 40910226)
16. Mizuguchi H, Sasaki T, Kawabata K, Sakurai F, Hayakawa T (2005) Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells. Biochem Biophys Res Commun 332: 1101-1106 (Pubitemid 40798198)
17. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J (2006) A comparison of the antitumor effects of interferon-a and b on human hepatocellular carcinoma cell lines. Cytokine 33: 121-128
18. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M (2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178: 5086-5098 (Pubitemid 46595292)
19. Parmar S, Platanias LC (2003) Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 15: 431-439 (Pubitemid 38147038)
20. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32 (Pubitemid 39576902)
21. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-l in murine tumor models. J Immunol 176: 7686-7694 (Pubitemid 43849069)
22. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68 (Pubitemid 36104710)
23. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-l) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017
24. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603 (Pubitemid 39534883)
25. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ (2006) IFN-b is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 66: 554-562 (Pubitemid 43166064)
26. Yoshida J, Mizuno M, Wakabayashi T (2004) Interferon-b gene therapy for cancer: basic research to clinical application. Cancer Sci 95: 858-865 (Pubitemid 40045519)
27. Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Uzawa K, Tanzawa H, Shimada H, Ochiai T, Tagawa M (2005) Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep 14: 831-835
28. Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer CJ (2006) Novel interferon-ls induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344: 1334-1341